Immune

Infections, immune support and inflammation-related immune claims. Ranked by evidence grade, then user score. Each grade is for the use named on the card, which may not be this goal.

• Sleep
• Recovery & injury
• Fat loss
• Cognition & mood
• Libido & sexual health
• Longevity
• Skin & hair
• Immune
• Muscle & strength

Evidence grade Any grade A only B or better C or better D or better US FDA Any status Approved for this useApproved for another use onlyNot approved WADA (sport) Any status Not prohibitedProhibited or likely prohibitedNot named / unclear

5 of 5 peptides shown

1. B

   1.Thymosin alpha-1

   Moderate human evidence · for immune support / infection defence

   FDA Not approved WADA Not named
   User scoretoo few reports (9)
   Men 45–60: 0 · everyone: 9 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; page tags mentions it; summary mentions it.

2. C

   2.Selank

   Preliminary human data · for anxiety relief

   FDA Not approved WADA Not named
   User score 3.0
   Outcomes: Positive 6 of 11 (55%), Mixed 1 of 11 (9%), Negative 1 of 11 (9%), No effect 2 of 11 (18%)
   Men 45–60: 0 · everyone: 11 reports · approximate

   Why it’s listed: page tags mentions it.

3. C

   3.Thymalin

   Preliminary human data · for immune 'rejuvenation', thymus regeneration and longevity

   FDA Not approved WADA Not named
   User scoretoo few reports (5)
   Men 45–60: 0 · everyone: 5 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; summary mentions it; 2 of 5 user reports mention immune.

4. C

   4.Vasoactive intestinal peptide

   Preliminary human data · for intranasal VIP for CIRS / chronic inflammation

   FDA Not approved WADA Not named
   User scoretoo few reports (9)
   Men 45–60: 0 · everyone: 9 reports · approximate

   Why it’s listed: summary mentions it.

5. D

   5.LL-37

   Preclinical only · for injected or nasal use for infections, biofilms and CIRS

   FDA Not approved WADA Prohibited (S0)
   User score 1.5
   Outcomes: Positive 4 of 23 (17%), Mixed 6 of 23 (26%), Negative 3 of 23 (13%), No effect 2 of 23 (9%), Unclear 6 of 23 (26%)
   Men 45–60: 0 · everyone: 23 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; summary mentions it; 9 of 23 user reports mention immune.

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.